An update to the language of the Biden administration’s proposed Build Back Better Act has been welcomed by the US Association for Accessible Medicines, after biosimilars and certain generic drugs were exempted from its planned inflation rebates – but the organization has still called for further changes to be made to the draft legislation.
The latest version of the bill now states that generic drugs under Medicare Part D that are in shortage can be exempted from the rebate provision, as well as biosimilars